MD Anderson will provide CCM with strategic counsel and programmatic services to support the development and execution of a multidisciplinary oncology plan with focus on clinical quality, individual safety, education and training, as well as research and development programs. The agreement, which is the first of its kind for MD Anderson in Asia, will end up being an exclusive collaboration at CCM's new cancer facilities in Beijing and Shanghai, and the collaboration exclusivity covers the majority of the provinces in China, and in Singapore.This award will allow Cerus to support ongoing advancement of the INTERCEPT reddish colored cell system. The award, granted by the U.S. Army Medical Analysis Acquisition Activity, between August 2011 and August 2012 covers a performance period. The award was granted to Cerus in recognition of the INTERCEPT crimson blood system’s potential to supply U.S. Military personnel with prospective safety against transfusion-transmitted diseases. To day, Cerus has received a lot more than $32 million in funding from the U.S. Division of Defense to boost blood safety for the U.S. Military.
AstraZeneca/Targacept’s TC-5214 for treatment resistant depression to earn Decision Assets’ gold standard status Decision Resources, among the world’s leading analysis and advisory companies for pharmaceutical and health care problems, finds that, for treatment resistant unhappiness therapy, AstraZeneca/Targacept’s TC-5214 can earn Decision Assets’ proprietary clinical gold regular status in 2013 and through 2018.